# Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

> **NCT05155033** · PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 78 (estimated)

## Conditions studied

- Metastatic Melanoma
- Advanced Locoregional Melanoma
- Metastatic Renal Cell Carcinoma
- Clear Cell Histology

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Aldesleukin

## Key facts

- **NCT ID:** NCT05155033
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-18
- **Primary completion:** 2031-09-01
- **Final completion:** 2031-09-01
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05155033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05155033, "Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT05155033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*